The Daily Biotech Pulse: Moderna’s Vaccine Produces Durable Response Against Variants, FDA Approves Jazz’s Sleep Disorder Drug, Dermata IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 12)
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 11)
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday morning, 67 companies achieved new lows for the year.
The Daily Biotech Pulse: FDA Rejects FibroGen’s Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 10)
Morgan Stanley Downgrades Epizyme to Underweight, Lowers Price Target to $5
Morgan Stanley analyst David Lebowitz downgrades Epizyme (NASDAQ:EPZM) from Equal-Weight to Underweight and lowers the price target from $10 to $5.
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck’s Keytruda On Track For More Label Expansions, Eliem Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 9)
HC Wainwright & Co. Maintains Buy on Epizyme, Lowers Price Target to $15
HC Wainwright & Co. analyst Andrew Fein maintains Epizyme (NASDAQ:EPZM) with a Buy and lowers the price target from $36 to $15.
